ZYXI News and Press, Zynex Inc. From 02/26/21

Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%,...

Image source: The Motley Fool. Zynex, Inc (NASDAQ: ZYXI) Q4 2020 Earnings Call Feb 25, 2021 , 4:15 p.m. ET Operator Continue reading For further details see: Zynex, Inc (ZYXI) Q4 2020 Earnings Call Transcript

Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform as it sees “higher downside risk”and less reward as clinical programs advance an...

Zynex, Inc. (ZYXI) Q4 2020 Results Earnings Conference Call February 25, 2021, 04:15 PM ET Company Participants Thomas Sandgaard - Founder, Chairman, and Chief Executive Officer Dan Moorhead - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright & Co. Jeffrey Coh...

Zynex Announces 2020 Fourth Quarter and Full Year Earnings PR Newswire ENGLEWOOD, Colo. , Feb. 25, 2021 /PRNewswire/ -- 2020 Full Year Revenue increased 76% year over year to $80.1 million Orders increased 96% Net...

Zynex Schedules 2020 Fourth Quarter and Full-Year Earnings Call PR Newswire ENGLEWOOD, Colo., Feb. 18, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical ...

Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical PR Newswire ENGLEWOOD, Colo., Jan. 28, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive m...

Medical technology company Zynex (ZYXI) has filed for a provisional patent for a noninvasive sepsis monitor for treating the life-threatening medical condition characterised by the body-wide inflammatory response or reaction that presents in response to infection.The signs and sympt...

Zynex Announces Filing of Patent for Sepsis Monitor PR Newswire ENGLEWOOD, Colo. , Jan. 14, 2021 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for...

Zynex ([[ZYXI]] +3.7%) reaffirms its previous revenue estimate for 4Q20 to be in rage of $25.5M and $26.5M vs. $25.60M consensus; and FY20 revenue estimate between $80M and $81M vs. $ 80.12M consensus.Zynex increases its adj. EBITDA estimate to between $3.1M and $4.1M (prior $2.3M and $3.3M);...